Further, a study showed that the gut microbiome plays a role on the therapeutic efficacy of prostate cancer immunotherapies —including cyclophosphamide and anti-PD-L1 therapies, and CTLA-4 blockade— and suggested that microbiome modulation may be a potential therapeutic strategy for prostate cancer [85]. This evidence concerns the gene CTLA4 and Familial prostate cancer.